Status:
COMPLETED
A Chart Review Study of Adults With Advanced NSCLC
Lead Sponsor:
Takeda
Conditions:
Non-small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
18+ years
Brief Summary
The main aim is to see how treatment patterns and drugs might improve care for adults with advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon-20 driven mutations. Past medi...
Detailed Description
This is a retrospective, observational study in participants with advanced NSCLC with EGFR exon-20 driven mutations. This study will look at clinical outcomes, patterns of care and disease management ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Histologically/cytologically confirmed diagnosis of locally advanced or metastatic (Stage IIb to IV) NSCLC with EGFR ex20ins mutations (based on the evaluation by the treating center) between 01 January 2017 and 30 November 2021.
- Followed-up at the site between 01 January 2017 and 30 November 2021 for his/her advanced NSCLC, irrespective of their current survival status.
- Exclusion Criteria
- 1\. Participants whose investigator has access to fewer than two registered visits for his/her advanced NSCLC between 01 January 2017 and 30 November 2021.
Exclusion
Key Trial Info
Start Date :
October 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 13 2023
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT05207423
Start Date
October 3 2022
End Date
February 13 2023
Last Update
February 28 2023
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
William Osler Health System
Brampton, Ontario, Canada, L6R 3J7
2
Grand River Hospital
Kitchener, Ontario, Canada, N2G 1G3
3
Ottawa Hospital Research Institute.
Ottawa, Ontario, Canada, K1H 8L6
4
University Health Network Princess Margaret Cancer Research Tower (PMCRT) The MaRS Centre, East Tower
Toronto, Ontario, Canada, M5G 1L7